Plasminogen activator inhibitor-1 4G/5G polymorphism and risk of stroke: Replicated findings in two nested case-control studies based on independent cohorts

Stroke

Volumn 36, Issue 8, 2005, Pages 1661-1665

  Wiklund, Per Gunnar ^a   Nilsson, Lennart ^b,c   Ardnor, Sofie Nilsson ^d   Eriksson, Per ^b   Johansson, Lars ^a   Stegmayr, Birgitta ^a   Hamsten, Anders ^b   Holmberg, Dan ^d   Asplund, Kjell ^a  

^a UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^d UMEÅ UNIVERSITY   (Sweden)

Author keywords

Genetics; Plasminogen activator inhibitor 1; Polymorphism; Stroke

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; BLOOD SAMPLING; CASE CONTROL STUDY; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; ENVIRONMENTAL FACTOR; FEMALE; FIBRINOLYSIS; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; HEREDITY; HOMOZYGOSITY; HUMAN; HYPERTRIGLYCERIDEMIA; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; PROMOTER REGION; SMOKING; STATISTICAL ANALYSIS; STROKE; SWEDEN;

ADULT; AGED; ALLELES; BLOOD PRESSURE; CASE-CONTROL STUDIES; CEREBROVASCULAR ACCIDENT; COHORT STUDIES; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; ISCHEMIA; MIDDLE AGED; ODDS RATIO; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); REGRESSION ANALYSIS; RISK; RISK FACTORS; SWEDEN; TIME FACTORS; TRANSCRIPTION, GENETIC; TRIGLYCERIDES;

EID: 23244465368     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000174485.10277.24     Document Type: Article

References (26)

1. Hamsten A, Eriksson P, Karpe F, Silveira A. Relationships of thrombosis and fibrinolysis 10 atherosclerosis. Curr Opin Lipidol. 1994;5:382-389.
2. Margaglione M, Di Minno G, Grandone E, Vecchione G, Celentano E, Cappucci G, Grilli M, Simone P, Panico S, Mancini M. Abnormally high circulation levels of tissue plasminogen activator and plasminogen activator inhibiior-1 in patients with a history of ischemic stroke. Arterioscler Thromb. 1994;14:1741-1745.
3. Lindgren A, Lindoff C, Norrving B, Åstedt B, Johansson BB. Tissue plasminogen activator and plasminogen activator inhibitor-1 in stroke patients. Stroke. 1996;27:1066-1071.
4. Catto AJ, Carter AM, Stickland M, Bamford JM, Davies JA, Grant PJ. Plasminogen activator inhibitor-1 (PAI-1) 4G/5G promoter polymorphism and levels in subjects with cerebrovascular disease. Thromb Haemost. 1997;77:730-734.
5. Johansson L, Jansson JH, Boman K, Nilsson TK, Stegmayr B, Hallmans G. Tissue plasminogen activator, plasminogen activator inhibitor-1, and tissue plasminogen activator/plasminogen activator inhibitor-1 complex as risk factors for the development of a first stroke. Stroke. 2000;31: 26-32.
6. Hamsten A, Eriksson P. Fibrinolysis and atherosclerosis. Baillieres Clin Haematol. 1995;8:345-363.
7. Festa A, D'Agostino R Jr, Rich SS, Jenny NS, Tracy RP, Haffner SM. Promoter (4G/5G) plasminogen activator inhibitor-1 genotype and plasminogen activator inhibitor-1 levels in blacks, Hispanics, and non-Hispanic whites: the Insulin Resistance Atherosclerosis Study. Circulation. 2003;107:2422-2427.
8. Bang CO, Park HK, Ahn MY, Shin HK, Hwang KY, Hong SY. 4G/5G polymorphism of the plasminogen activator inhibitor-1 gene and insertion/deletion polymorphism of the tissue-type plasminogen activator gene in atherothrombotic stroke. Cerebrovasc Dis. 2001;11:294-299.
9. Hindorff LA, Schwartz SM, Siscovick DS, Psaty BM, Longstreth WT Jr, Reiner AP. The association of PAI-1 promoter 4G/5G insertion/deletion polymorphism with myocardial infarction and stroke in young women. J Cardiovasc Risk. 2002;9:131-137.
10. Roest M, van der Schouw YT, Banga JD, Tempelman MJ, de Groot PG, Sixma JJ, Grobbee DE. Plasminogen activator inhibitor 4G polymorphism is associated with decreased risk of cerebrovascular mortality in older women. Circulation. 2000;101:67-70.
11. Endler G, Lalouschek W, Exner M, Mitterbauer G, Haring D, Mannhalter C. The 4G/4G genotype at nucleotide position -675 in the promotor region of the plasminogen aclivalor inhibitor 1 (PAI-1) gene is less frequent in young patients with minor stroke than in controls. Br J Haematol. 2000;110:469-471.
12. Hoekstra T, Geleijnse JM, Kluft C, Giltay EJ, Kok FJ, Schoulen EG. 4G/4G genotype of PAI-1 gene is associated with reduced risk of stroke in elderly. Stroke. 2003;34:2822-2828.
13. Eriksson P, Nilsson L, Karpe F, Hamsten A. Very-low-density lipoprotein response element in the promoter region of the human plasminogen activator inhibitor-1 gene implicated in the impaired fibrinolysis of hypertriglyceridemia. Arterioscler Thromb Vasc Biol. 1998;18:20-26.
14. Colhoun HM, McKeigue PM, Davey Smith G. Problems of reporting genetic associations with complex outcomes. Lancet. 2003;361:865-872.
15. Kuulasmaa K, Tunstall-Pedoe H, Dobson A, Fortmann S, Sans S, Tolonen H, Evans A, Ferrario M, Tuomilehto J. Estimation of contribution of changes in classic risk factors to trends in coronary-event rates across the WHO MONICA project populations. Lancet. 2000;355: 675-687.
16. Stegmayr B, Lundberg V, Asplund K. The events registration and survey procedures in the Northern Sweden MONICA project. Scand J Public Health Suppl. 2003;61:9-17.
17. WHO Study Group. Diabetes mellitus. World Health Organization Technical Report, series 727, 1995.
18. Margaglione M, Grandone E, Cappucci G, Colaizzo D, Giuliani N, Vecchione G, d'Addedda M, Di Minno G. An alternative method for PAI-1 promoter polymorphism (4G/5G) typing. Thromb Hoemost. 1997; 77:605-606.
19. Eriksson P, Kallin B, van't Hooft FM, Båvenholm P, Hamsten A. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor I gene is associated with myocardial infarction. Proc Natl Acad Sci U S A. 1995;92:1851-1855.
20. Panahloo A, Mohamed-Ali V, Lane A, Green F, Humphries SE, Yudkin JS. Determinants of plasminogen activator inhibitor I activity in treated N1DDM and its relation to a polymorphism in the plasminogen activator inhibitor I gene. Diabetes. 1995;44:37-42.
21. Roest M, Banga JD. Editorial comment-genetic make-up for increased PAI-1 expression protects against stroke. Stroke. 2003;34:2828-2829.
22. Hamsten A, Wiman B, de Faire U, Blombäck M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med. 1985;313:1557-1563.
23. Kohler HP, Grant PJ. Plasminogen-activator inhibitor type I and coronary artery disease. N Engl J Med. 2000;342:1792-1801.
24. Folsom AR. Hemostatic risk factors for atherothrombotic disease: an epidemiologic view. Thromb Haemost. 2001;86:366-373.
25. Casas JP, Hingorani AD, Bautista LE, Sharma P. Meta-analysis of genetic studies in ischemic stroke: thirty-two genes involving approximately 18 000 cases and 58 000 controls. Arch Neurol. 2004;61:1652-1661.
26. Little J, Bradley L, Bray MS, Clyne M, Dorman J, Ellsworth DL, Hanson J, Khoury M, Lau J, O'Brien TR, Rothman N, Stroup D, Taioli E, Thomas D, Vainio H, Wacholder S, Weinberg C. Reporting, appraising, and integrating data on genotype prevalence and gene-disease associations. Am J Epidemiol. 2002;156:300-310.